ENPICOM

ENPICOM, founded in 2016 and headquartered in 's-Hertogenbosch, Netherlands, is a bioinformatics software company specializing in accelerating biologics discovery and development.

Reviewed by 7wData
Share Email

On this page

Profile

They develop AI-driven software to accelerate biologics discovery and development.

ENPICOM, founded in 2016 and headquartered in 's-Hertogenbosch, Netherlands, is a bioinformatics software company specializing in accelerating biologics discovery and development. The company focuses on integrating AI into biologics workflows, offering a unified platform that combines bioinformatics, data foundation, and machine learning frameworks. ENPICOM’s approach is structured around a three-step blueprint: building a robust data foundation, automating bioinformatics pipelines, and integrating AI to enhance decision-making in biologics discovery.

The company has gained traction among global pharmaceutical leaders and research institutions, with notable clients including Illumina, LifeArc, and Erasmus MC. ENPICOM’s IGX Platform, a flagship product, enables researchers to analyze antibody display data efficiently, facilitating the identification of diverse candidates with optimal characteristics. In 2025, ENPICOM expanded its capabilities with the launch of the IGX-Track App, which streamlines antibody panning data analysis.

The company’s financial trajectory remains undisclosed, but its focus on AI-driven solutions positions it within the growing digital health sector, which saw $14.2 billion in funding in 2025, largely driven by AI advancements. ENPICOM’s emphasis on automating and scaling biologics discovery workflows aligns with broader industry trends toward AI-enabled innovation.

Track ENPICOM and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies
  • Biotech research firms
  • Academic research institutions
  • Healthcare innovation labs

Publicly disclosed clients

  • Illumina
  • LifeArc
  • Erasmus MC

Strengths and what to watch

Strengths

  • Integration of AI into biologics discovery workflows
  • Trusted by top-tier pharmaceutical and research institutions
  • Focus on scalable, automated bioinformatics solutions

Watch for

  • Competition from larger AI-driven biotech firms
  • Dependence on AI adoption rates in the biologics sector
  • Potential challenges in scaling operations globally

Key Information

Founded
2015

Frequently Asked Questions

What does ENPICOM do?

ENPICOM develops AI-powered bioinformatics software to accelerate biologics discovery. Founded in 2016, their platform integrates machine learning with antibody data analysis, helping pharmaceutical and research institutions streamline workflows. Their IGX Platform enables efficient antibody candidate identification, trusted by clients like Illumina and Erasmus MC.

How does ENPICOM use AI in biologics?

ENPICOM applies AI across a three-step biologics workflow: building data foundations, automating bioinformatics pipelines, and enhancing decision-making. Their system analyzes antibody display data to identify optimal candidates, reducing manual effort. The approach combines machine learning frameworks with domain-specific biological knowledge for precision.

What is the IGX Platform used for?

ENPICOM's IGX Platform specializes in antibody display data analysis, helping researchers identify diverse candidates with desired characteristics. It provides a unified environment combining bioinformatics tools and AI, enabling faster selection processes. The 2025 IGX-Track App extension further streamlined antibody panning data analysis.

Who uses ENPICOM's software?

ENPICOM serves pharmaceutical companies, biotech research firms, and academic institutions. Notable clients include Illumina, LifeArc, and Erasmus MC. Their solutions target organizations scaling biologics discovery through automation, particularly those working with antibody development and requiring AI-enhanced bioinformatics capabilities.

How does ENPICOM compare to other bioinformatics platforms?

ENPICOM differentiates through specialized AI integration for antibody discovery, trusted by top-tier institutions. While facing competition from larger biotech AI firms, their focus on scalable, automated workflows for biologics gives them niche strength. The platform combines data foundations with machine learning for end-to-end solutions.

What trends support ENPICOM's growth?

ENPICOM benefits from the $14.2B digital health AI funding surge (2025) and industry adoption of AI in biologics. Their automated workflows align with pharma's need for faster discovery cycles. However, growth depends on broader AI acceptance in biologics and ability to scale operations globally against competitors.

Sources

  1. enpicom.com — Company overview and product details
  2. enpicom.com — Launch of IGX-Track App
  3. www.fiercehealthcare.com — Digital health funding trends in 2025
  4. investors.dexcom.com — Context on AI-driven healthcare growth